Two top GlaxoSmithKline executives are to receive retention packages worth £2m after missing out two months ago on becoming chief executive of the pharmaceuticals giant.
Chris Viehbacher (bottom), president of Glaxo's US pharmaceutical business, and David Stout (top), president of pharmaceutical operations, are being offered the retention payments as well as a seat on the £71bn company's board after being overlooked for the top job.
The post was handed to its European president of pharmaceuticals, Andrew Witty, in October.
More
Chris Viehbacher (bottom), president of Glaxo's US pharmaceutical business, and David Stout (top), president of pharmaceutical operations, are being offered the retention payments as well as a seat on the £71bn company's board after being overlooked for the top job.
The post was handed to its European president of pharmaceuticals, Andrew Witty, in October.
More
1 comment:
When losers become winners, they share their experience (Jean-Claude Lerroy)
Post a Comment